# EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection

> **NCT00006436** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 68 (actual)

## Conditions studied

- Lymphoma, AIDS-related
- Lymphoma, Large B-Cell, Diffuse

## Interventions

- **BIOLOGICAL:** Rituximab
- **BIOLOGICAL:** Filgrastim
- **DRUG:** EPOCH

## Key facts

- **NCT ID:** NCT00006436
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-01-29
- **Primary completion:** 2020-11-30
- **Final completion:** 2024-01-18
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006436, "EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00006436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*